| Literature DB >> 30023050 |
Sarah G Moxon1, Tanya Guenther2, Sabine Gabrysch3, Christabel Enweronu-Laryea4, Pavani K Ram5,6, Susan Niermeyer5,7, Kate Kerber2, Cally J Tann1,8, Neal Russell1, Lily Kak5, Patricia Bailey9, Sasha Wilson8, Wenjuan Wang10, Rebecca Winter10, Liliana Carvajal-Aguirre11, Hannah Blencowe1, Oona Campbell1, Joy Lawn1.
Abstract
BACKGROUND: Each year an estimated 2.6 million newborns die, mainly from complications of prematurity, neonatal infections, and intrapartum events. Reducing these deaths requires high coverage of good quality care at birth, and inpatient care for small and sick newborns. In low- and middle-income countries, standardised measurement of the readiness of facilities to provide emergency obstetric care has improved tracking of readiness to provide care at birth in recent years. However, the focus has been mainly on obstetric care; service readiness for providing inpatient care of small and sick newborns is still not consistently measured or tracked.Entities:
Mesh:
Year: 2018 PMID: 30023050 PMCID: PMC6038996 DOI: 10.7189/jogh.08.010702
Source DB: PubMed Journal: J Glob Health ISSN: 2047-2978 Impact factor: 4.413
Figure 1Evidence-based newborn care interventions from basic to complex care. There are additional evidence-based interventions for newborns that should be included in the antenatal period – antenatal corticosteroids and antibiotics for preterm premature rupture of membranes - and follow-up processes that would fall outside of the newborn period and be linked to paediatric services. Figure adapted from [8]. Photo credit (from top to bottom) Ayesha Vellani/Save the Children, ©EFCNI, JHPIEGO.
Figure 2The Donabedian framework applied as a construct to map health facility assessment tools.
Resource materials and guidelines reviewed for newborn interventions
| Intervention | Resource material or guideline | Year published |
|---|---|---|
| Essential newborn care, thermal protection, early initiation and support for exclusive breastfeeding | WHO essential newborn care course | 2010 |
| WHO early essential newborn care: Clinical practice pocket guide | 2014 | |
| Essential care for every baby | 2015 | |
| WHO Integrated management of pregnancy and childbirth: Pregnancy, Childbirth, Postpartum and Newborn Care: A guide for essential practice | 2015 | |
| UNICEF: Baby Friendly Hospital Initiative (BFHI) | 2012 | |
| WHO Interagency list of priority medical devices for essential interventions for reproductive, maternal, newborn and child health | 2015 | |
| Neonatal resuscitation | WHO guidelines on basic newborn resuscitation | 2012 |
| Helping Babies Breathe Resources | 2017 | |
| WHO guidelines on managing complications in pregnancy and childbirth | 2007 | |
| WHO guidelines on managing newborn problems: a guide for doctors, nurses and midwives | 2003 | |
| Prevention of mother to child transmission of HIV | WHO guideline update on HIV and infant feeding | 2016 |
| WHO guidelines on antiretroviral drugs for treating pregnant women and preventing HIV infection in infants | 2010 | |
| Médecins sans Frontières: Neonatal Care Guidelines | 2016 | |
| Kangaroo mother care for premature babies, including follow up, alternative feeding (cup feeding and nasogastric feeding) | Essential care for small babies | 2015 |
| WHO kangaroo mother care: A practical guide | 2003 | |
| WHO guidelines on optimal feeding of low birth-weight infants in low- and middle-income countries | 2011 | |
| UNHCR operational guidelines on improving newborn health in refugee operations | 2014 | |
| UNICEF toolkit for setting up special care newborn units, stabilisation units and newborn care corners | 2015 | |
| WHO recommendations on interventions to improve preterm birth outcomes | ||
| Injectable antibiotics for neonatal infections, hypoglycaemia management, effective phototherapy, seizure management, administration of oxygen | WHO pocket book of hospital care for children | 2013 |
| Save the Children, UNICEF: Newborn care charts | 2009 | |
| Treatment and screening for retinopathy of prematurity* | Guidelines on screening and treatment for retinopathy of prematurity (UK and India) | 2008 |
| Blood transfusion, Mechanical ventilation and continuous positive airway pressure (CPAP) | WHO pocket book of hospital care for children | 2013 |
*No current WHO guidelines available; recent guidelines recommended by ROP experts from India and UK selected for review.
Example minimum drug list for inpatient care of small and sick newborns showing rationale for use in newborns and summary of the Service Provision Assessment (SPA), Service Availability and Readiness Assessment (SARA) and Emergency Obstetric and Newborn Care (EmONC) Assessment tools and Essential Medicines List*
| Drug name | SPA | SARA | EmONC | EML | Drug description/use |
|---|---|---|---|---|---|
| Amoxicillin (oral suspension) | Y | Y | Y | Y | Penicillin antibacterial for neonatal infections |
| Amoxicillin (injection) | Y | Y | Penicillin antibacterial for serious neonatal infections | ||
| Amikacin (IV or IM) | Y | Aminoglycoside antibacterial; alternative treatment of opthalmia neonatorum | |||
| Ampicillin (IV or IM) | Y | Y | Y | Y | Penicillin antibacterial for serious neonatal infections |
| Ampicillin (oral) | Penicillin antibacterial for neonatal infections | ||||
| Azithromycin (oral) | Y | Y | Y | Macrolide antibacterial for P-PROM (maternal use) | |
| Benzathine benzylpenicillin (benzathine penicillin G) (IM) | Y | Y | Y | Penicillin antibacterial for treatment of congenital syphilis | |
| Benzylpenicillin (Penicillin G) (IV or IM) | Y | Y | Y | Penicillin antibacterial for serious neonatal infections | |
| Cefalexin (oral suspension) | Y | First generation cephalosporin used in newborns for skin and soft tissue infections | |||
| Cefotaxime (IV or IM) | Y | Y | First generation cephalosporin with broad spectrum for treatment of serious neonatal infections | ||
| Ceftriaxone (IV or IM) | Y | Y | Y | Third generation cephalosporin for neonatal infections, genital gonococcal and/or chlamydial infection | |
| Ciprofloxacin (injection) | Y | Second generation fluoroquinolone antibacterial sometimes used as second line treatment | |||
| Ciprofloxacin (oral) | Y | Y | Y | Second generation fluoroquinolone antibacterial for treatment of bacterial diarrhoea | |
| Clindamycin (IV) | Y | Y | Lincosamide antibacterial, second line treatment (eg, streptococcal or soft tissue infections) | ||
| Co-amoxiclav (oral suspension) | Y | Penicillin antibacterial, can be used where no IV access | |||
| Co-amoxiclav (injection) | Penicillin antibacterial used for neonatal skin infections | ||||
| Cotrimoxazole (oral) | Y | Y | Combined antibacterial for prophylactic treatment of HIV | ||
| Erythromycin (oral) | Y | Y | Y | Macrolide antibacterial for P-PROM (maternal use) | |
| Flucloxacillin (IV/IM) (cloxacillin) | Y | Y | Penicillin antibacterial treatment for neonatal sepsis | ||
| Flucloxacillin (oral) | Y | Y | Penicillin antibacterial. Can be used in newborns as follow on from intravenous flucloxacillin | ||
| Gentamicin (IM or IV) | Y | Y | Y | Y | Aminoglycoside antibacterial used for treatment of neonatal sepsis |
| Isoniazid (oral) | Y | Y | Y | Antituberculous antibacterial used occasionally for congenital TB | |
| Kanamycin | Y | Aminoglycoside antibacterial; alternative to gentamicin | |||
| Metronidazole (IV) | Y | Y | Y | Y | Antiprotozoal antibacterial used for neonatal meningitis and/or anaerobic bacterial infections |
| Metronidazole (oral) | Y | Y | Y | Antiprotozoal antibacterial used for neonatal meningitis and/or anaerobic bacterial infections | |
| Procaine benzylpenicillin (IM) | Y | Y | Y | Penicillin antibacterial used for congenital syphilis | |
| Tetracycline 1% eye ointment | Y | Y | Y | Y | Prophylactic topical antibiotic used to prevent bacterial (eg, chlamydial, gonococcal) neonatal conjunctivitis |
| Diazepam (oral/NG) | Y | Sedative, anticonvulsant, muscle relaxant, mostly used for neonatal tetanus | |||
| Diazepam emulsion (IV) | Y | Y | Y | Y | Sedative, anticonvulsant, muscle relaxant used for neonatal tetanus |
| Midazolam (oral solution) | Y | Sedative, anticonvulsant used for seizures | |||
| Paraldehyde (rectal) | Anticonvulsant for seizures | ||||
| Phenobarbital (IV or IM) | Y | Y | Y | First line anticonvulsant for tonic clonic and partial seizures | |
| Phenobarbital (oral) | Y | Y | First line anticonvulsant for tonic clonic and partial seizures | ||
| Phenytoin (IV) | Y | Y | Anticonvulsant for tonic clonic and partial seizures | ||
| Adrenaline/epinephrine (IV) | Y | Y | Y | Y | Sympathomimetic for cardiopulmonary arrest used for advanced neonatal resuscitation |
| Aminophylline | Y | Methylzanthine used to prevent apnoeic attacks in premature newborns | |||
| Atropine (injection) | Y | Y | Y | Parasympatholytic, antispasmodic used for intubation | |
| Calcium gluconate (injection) | Y | Y | Y | Y | Used for hypocalcaemic seizures and hyperkalaemia |
| Hydrocortisone (injection) | Y | Y | Y | Steroidal anti-inflammatory used for hypotension or severe broncho-pulmonary dysplasia | |
| Magnesium sulphate (IV) | Y | Y | Y | Y | Inorganic salt compound, maternal use in preterm labour, protective against cerebral palsy |
| Naloxone (IV) | Y | Y | Specific opioid antagonist for respiratory depression in newborns | ||
| Ibuprofen (IV) | Y | Analgesic sometimes used in newborns for closing patent ductus arteriosus | |||
| Morphine (IV) | Y | Y | Y | Centrally acting opioid analgesic for severe pain, sedation and intubation | |
| Morphine (oral) | Y | Y | Y | Used for severe pain | |
| Paracetamol (oral) | Y | Y | Y | Y | Analgesic for minor pain |
| Paracetamol (suppository) | Y | Analgesic for minor pain | |||
| Paracetamol (injection) | Analgesic for minor pain. Also used for newborns for closing patent ductus arteriosus. | ||||
| Betamethasone (IM) | Y | Y | Y | Not used in newborns; used in mothers with threatened preterm labour <34 weeks gestation for fetal lung maturation | |
| Dexamethasone (IM) | Y | Y | Y | Y | Not used in newborns; used in mothers with threatened preterm labour <34 weeks gestation for fetal lung maturation |
| Calcium gluconate 10% | Y | Y | Y | Supplement used to treat calcium deficiency. Dependent on programme context – careful monitoring required | |
| Dextrose 10% with normal saline | Y | Y | Y | Solution used for maintainance fluid therapy | |
| Dextrose/glucose 5% | Y | Y | Y | Y | Solution used as vehicle for administration of IV drugs |
| Dextrose/glucose 10% | Y | Y | Y | Solution for treatment of hypoglycaemia and maintenance fluid therapy on first day of life for sick babies who cannot feed | |
| Potassium chloride (KCl) 7.5%, 10%, 15% | Y | Solution only to be used in contexts where monitoring of potassium levels is available. | |||
| Sodium bicarbonate | Y | Solution used to dissolve artesunate | |||
| Sodium chloride 0.9% | Y | Y | Y | Y | Solution used as a vehicle for administration of IV/parenteral drugs, fluid replacement and flushing IV lines |
| Ringer’s lactate | Y | Y | Y | Y | Compound solution for severe dehydration/hypovolaemia can be added to dextrose/glucose for a mix |
| Water for injection | Sterile water for mixing drugs | ||||
| Artesunate (IV or IM) | Y | Y | Y | First line treatment for neonatal malaria | |
| Artesunate (rectal) | Y | Y | Y | Neonatal malaria treatment if IV/IM access not available | |
| Arthemeter (IM) | Y | Second line treatment for neonatal malaria | |||
| Artemisinin-based combined therapy (oral) | Y | Y | Y | Y | Second line anti-malarial treatment followed by ACT |
| Azidothymidine/Zidovudine (AZT) (oral) | Y | Y | Y | Y | Antiretroviral |
| Lamivudine | Y | Y | Y | Y | Antiretroviral |
| Nevirapine (NVP) (oral) | Y | Y | Y | Y | Antiretroviral |
| Aciclovir (IV) | Y | Antiviral used for herpes | |||
| Acyclovir 3% topical eye ointment | Y | Antiviral active against herpes virus used to prevent neonatal herpes keratitis in babies born to mother with genital herpes | |||
| Anti-Rho (D) immune globulin (injection) | Y | To prevent Rhesus disease (haemolytic disease of the newborn) given to mothers | |||
| Caffeine citrate (oral) | Y | Preventive treatment for apnoea | |||
| Caffeine citrate (IV) | Y | Preventive treatment for apnoea, oral preferred over IV | |||
| Chlorhexidine digluconate 7.1% gel (delivering 4% chlorhexidine) | Y | Y | Y | Topical treatment of omphalitis | |
| Domperidone | Anti-reflux drug for gastro-oesophageal reflux | ||||
| Ethambutamol (oral) | Y | Y | Y | First line oral anti-tuberculolous drug | |
| Ferrous fumerate (oral) | Y | Y | Y | Oral suspension used for preterm neonates to prevent iron deficiency | |
| Folic acid | Y | Y | Y | Y | Oral suspension used for folate supplementation |
| Fluconazole (IV) | Y | Antifungal drug used in newborns over 1 week | |||
| Fluconazole (oral) | Y | Y | Y | Y | Antifungal drug |
| Furosemide (IV) | Y | Y | Diuretic used for chronic lung disease, oedema in advanced settings | ||
| Furosemide (oral) | Y | Y | Y | Diuretic | |
| Glycerin chip | Suppository used in newborns to stimulate stooling | ||||
| Hepatitis B immune globulin (HBIG) | Treatment of Hepatitis B in neonates | ||||
| Human milk fortifier | Fortifier, adds protein, calories and micronutrients to expressed breastmilk for LBW babies | ||||
| Insecticxide treated bed nets (in malaria endemic areas) | Y | Y | Y | For mother’s beds in KMC ward and for discharge home | |
| Lidocaine solution | Y | Y | Y | Y | Local anaesthetic |
| Miconazole cream (or equivalent eg, gentian violet) | Y | Y | Topical antifungal for candida dermatitis used for nappy area | ||
| Multivitamin | Containing zinc, vitamin A etc. | ||||
| Nystatin (oral solution) | Y | Y | Y | Topical antifungal for oropharyngeal candidiasis used prophylactically with antibiotic treatment | |
| Nystatin cream | Y | Topical antifungal | |||
| Omeprazole (IV) | Y | Y | Acid blocker for gastro-oesophageal reflux | ||
| Omeprazole (oral) | Y | Y | Acid blocker for gastro-oesophageal reflux | ||
| Oral rehydration solution | Y | Y | Y | Y | Powder to mix with drinking water for oral rehydration; breastmilk feeding should be encouraged |
| Oxygen supply | Y | Medical inhalation gas for treatment of respiratory distress | |||
| Phosphate and calcium supplements | Supplementation | ||||
| Potassium Chloride (1mmol/ml) (oral) | Y | Powder solution for maintainance oral potassium replacement | |||
| Pyridoxine (oral) | Y | Preventive therapy for tuberculosis | |||
| Pyrazinamide (oral) | Y | Y | Y | First line oral anti-tuberculolous drug | |
| Ranitidine (IV) | Y | Antacid drug for gastro-oesophageal reflux | |||
| Ranitidine (oral) | Y | Antacid drug for gastro-oesophageal reflux | |||
| Rifampicin (oral) | Y | Y | Y | First line oral anti-tuberculolous drug | |
| Sucrose 30% (oral) | Non-pharmacological pain management for minor procedures (eg, cannulation) | ||||
| Tetanus immunoglobulin (HTIG) (IM) | Y | Y | Anti-tetanus immunoglobulin for treatment of neonatal tetanus | ||
| Vitamin B6 (pyridoxine) (IV or IM) | Vitamin for B6 deficiency | ||||
| Vitamin D | Supplementation. | ||||
| Vitamin K1 (Phytomenadione) (IM or IV) | Y | Y | Vitamin and anti-haemorrhagic for prophylactic treatment of haemorrhagic disease of the newborn | ||
| Water based lubricant | For inserting suppositories and/or other procedures. | ||||
| Zinc oxide cream | Topical for nappy/diaper rash | ||||
| Vaccines: | |||||
| BCG vaccine | Y | Y | Y | Y | Prevention of TB |
| Diptheria | Y | Y | Y | Prevention of diptheria | |
| Pertussis vaccine | Y | Y | Y | Prevention of pertussis | |
| Y | Y | Y | Prevention of haemophilis influenzae type B | ||
| Hepatitis B vaccine | Y | Y | Y | Prevention of hepatitis B in countries where perinatal infection is common, as per vaccination schedule | |
| Oral poliomyelitis vaccine | Y | Y | Y | Y | Prevention of poliomyelitis |
| Tetanus toxoid | Y | Y | Y | Y | Prevention of tetanus in wound management, prevention of maternal and neonatal tetanus in pregnant women |
EmONC – Emergency Obstetric and Newborn Care, SPA – Service Provision Assessment, SARA – Service Availability and Readiness Assessment, EML – Essential Medicines List, IM – intramuscular, IV – intravenous, NG – nasogastric
*Y – measured by the tool.
Summary of three multi-country health facility assessment tools: Service Provision Assessment (SPA), Service Availability and Readiness Assessment (SARA) and Emergency Obstetric and Newborn Care (EmONC) Assessment
| Service Provision Assessments (SPA) | Service Availability and Readiness Assessment (SARA) | Emergency Obstetric and Newborn Care (EmONC) Assessment | |
|---|---|---|---|
| For comprehensive monitoring of a country’s formal health care system; monitors the overall availability of different facility-based health services in a country and their readiness to provide those services | For assessing readiness of facilities using a standard set of indicators that cover all main health programmes. Only designed to assess service readiness (not performance or client perspectives) | For monitoring and assessment of the availability, use and quality of routine and emergency obstetric and newborn care in the formal health system. | |
| The Demographic and Health Survey (DHS) Program, United States Agency for International Development (USAID) | World Health Organization (WHO), USAID | Averting Maternal Death & Disability (AMDD), United Nations Population Fund (UNFPA), United Nations Children’s Fund (UNICEF), WHO. | |
| Sample survey or census of formal sector health facilities designed to provide nationally representative results by facility type, managing authority, and geographic region. | Sample survey or census of at least 150 public and private facilities | Census of hospitals and census or sample of lower-level delivery sites (public and private facilities). Sample may be random or selection may be restricted to lower-level facilities that meet a specific volume of deliveries. | |
| Facility inventory, exit interviews (antenatal care, family planning, sick child), clinical observations (antenatal care, family planning, sick child), health worker provider interviews | Facility inventory, health worker interview | Facility inventory, human resources, essential drugs, equipment and supplies, facility case summary, Emergency Obstetric Care (EmOC) signal functions, provider knowledge for maternal and some newborn care & chart reviews. | |
| Number of facilities ready to provide MNCH, family planning, HIV/AIDS, STIs, Malaria, Tuberculosis, basic surgery, non-communicable diseases services. | Proportion of health facilities, number of core medical professionals, proportion of facilities offering a defined service and the density and distribution of the facilities | Number of facilities providing EmOC, number of facilities providing each EmOC signal functions by level of care. | |
| All formal facilities | All facilities, per 10 000 population | All surveyed facilities by level of care; availability of EmOC is measured per 500 000 population or 20 000 births* | |
| 15-18 months to complete fieldwork and report | Variable, but shorter than SPA or EmONC | 12-18 months to complete field work and report | |
| 4-5 yearly intervals | Designed to be repeated annually | 4-5 yearly intervals |
*Discussion is ongoing on whether denominator should measure births or population); expected number of births is the denominator for several other indicators – institutional birth rate, caesarean-section rate, met need for emergency obstetric care.
A summary of the Service Provision Assessment (SPA), Service Availability and Readiness Assessment (SARA) and Emergency Obstetric and Newborn Care (EmONC) assessment tools’ capacity to measure structural and process domains of service readiness for newborn interventions in the labour and delivery room
| Intervention and components of structural domain | Health facility assessment tool | ||
|---|---|---|---|
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | Y | Y |
| Guidelines | Y | Y | |
| Training | Y | Y | Y |
| Routine practice | Y | Y | Y |
| Infrastructure | Y | Y | Y |
| Equipment & drugs | |||
| Guidelines | Y | Y | Y |
| Training | Y | ||
| Routine practice | Y | Y | |
| Infrastructure | |||
| Equipment & drugs | Y | ||
| Guidelines | Y | Y | |
| Training | Y | Y | Y |
| Routine practice | Y | Y | Y |
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | Y | Y |
| Guidelines | Y | Y | Y |
| Training | Y | Y | Y |
| Routine practice | Y | Y | Y |
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | Y | Y |
| Guidelines | Y | Y | Y |
| Training | Y | Y | Y |
| Routine practice | Y | Y | Y |
EmONC – Emergency Obstetric and Newborn Care, SPA – Service Provision Assessment, SARA – Service Availability and Readiness Assessment
*Y – measured by the tool.
†May only be applicable in settings with high HIV prevalence.
A summary of the Service Provision Assessment (SPA), Service Availability and Readiness Assessment (SARA) and Emergency Obstetric and Newborn Care (EmONC) tools’ capacity to measure the structural and process domain of service readiness for interventions in the newborn inpatient care unit
| Intervention and components of structural domain | Health facility assessment tool | ||
|---|---|---|---|
| Infrastructure | |||
| Equipment & drugs | |||
| Guidelines | Y | ||
| Training | Y | Y | |
| Routine practice | Y | Y | Y |
| Infrastructure | |||
| Equipment & drugs | |||
| Guidelines | |||
| Training | |||
| Routine practice | Y | ||
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | ||
| Guidelines | Y | ||
| Training | Y | ||
| Routine practice | Y | ||
| Infrastructure | |||
| Equipment & drugs | Y | ||
| Guidelines | Y | ||
| Training | Y | Y | |
| Routine practice | Y | Y | |
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | Y | Y |
| Guidelines | Y | Y | Y |
| Training | Y | Y | |
| Routine practice | Y | Y | |
| Infrastructure | |||
| Equipment & drugs | |||
| Guidelines | |||
| Training | |||
| Routine practice | |||
| Infrastructure | Y | Y | Y |
| Equipment & drugs | Y | Y | Y |
| Guidelines | |||
| Training | |||
| Routine practice | |||
| Infrastructure | Y | Y | Y |
| Equipment & drugs | |||
| Guidelines | |||
| Training | |||
| Routine practice | |||
| Infrastructure | Y | Y | Y |
| Equipment & drugs | |||
| Guidelines | |||
| Training | |||
| Routine practice | |||
| Infrastructure | |||
| Equipment & drugs | |||
| Guidelines | |||
| Training | |||
| Routine practice | |||
EmONC – Emergency Obstetric and Newborn Care, SPA – Service Provision Assessment, SARA – Service Availability and Readiness Assessment
*Y – measured by the tool.
The approach used by Service Provision Assessment (SPA), Service Availability and Readiness Assessment (SARA) and Emergency Obstetric and Newborn Care (EmONC) to measure regular practice and training
| SPA | SARA | EmONC | ||||
|---|---|---|---|---|---|---|
| Essential newborn care | Routinely practiced | Training in last 24 months | Routinely carried out | Training in last 24 months | Performed in last 3 months | Ever received training |
| Thermal protection | Training in last 24 months | As part of essential newborn care | As part of essential newborn care | |||
| Early initiation and support for exclusive breastfeeding | Routinely practiced | Training in last 24 months | Routinely carried out | Training in last 24 months | As part of essential newborn care | As part of essential newborn care |
| Neonatal resuscitation with bag and mask | Ever practiced, practiced in last 3 months | Training in last 24 months | Practiced in last 12 months | Training in last 24 months | Performed in last 3 months | Ever received training |
| Prevention of mother to child transmission of HIV | Routinely practiced | Training in last 24 months | Service is offered | Training in last 24 months | ARVs given to newborns in the last 3 months | Ever received training |
| Kangaroo mother care | Ever practiced | Training in last 24 months | Practiced in last 12 months | Performed in the last 3 months | Ever received training | |
| Assisted feeding (cup feeding and nasogastric feeding) | Performed in last 3 months | |||||
| Safe administration of oxygen | Performed in last 3 months | |||||
| Injectable antibiotics for neonatal infection | Training in last 24 months | Practiced in last 12 months | Performed in last 3 months | Ever received training | ||
| Intravenous fluid | Training in last 24 months | Performed in last 3 months | ||||
EmONC – Emergency Obstetric and Newborn Care, SPA – Service Provision Assessment, SARA – Service Availability and Readiness Assessment